Histologic maturation of cerebral neuroblastoma following conventional chemotherapy

Bidgoli, Alan; McLendon, Roger E.; Johnston, Jonathan B.

doi:10.1002/pbc.29034

Cited by 2 publications

(6 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Post‐chemotherapy, the resected tumor tissue was no longer WHO Grade IV, but a WHO Grade I ganglioglioma, inferring maturation and differentiation from the original tumor tissue biopsied pre‐treatment. 15 As with all of the cases discussed thus far, there was impressive regression of tumor bulk. Additionally, the patient was alive and well over 3 years from initial diagnosis at the time of publication.…”

Section: Discussionmentioning

confidence: 51%

“…As with all of the cases discussed thus far, there was impressive regression of tumor bulk. Additionally, the patient was alive and well over 3 years from initial diagnosis at the time of publication 15 . Driever et al 16 reported a case of a 5‐year‐old male who was diagnosed on histopathology with an undifferentiated WHO Grade IV PNET with focal neuronal differentiation.…”

Section: Discussionmentioning

confidence: 97%

“…Additionally, the patient was alive and well over 3 years from initial diagnosis at the time of publication. 15 Driever et al 16 reported a case of a 5‐year‐old male who was diagnosed on histopathology with an undifferentiated WHO Grade IV PNET with focal neuronal differentiation. Following chemoradiation, a local recurrence of the tumor showed loss of the initial small, round, blue cells and expression of glial fibrillary acid protein (GFAP), inferring differentiation along the astrocytic lineage.…”

Section: Discussionmentioning

confidence: 99%

“…Additionally, Bidgoli et al 15 reported on a 7‐week‐old female diagnosed with an embryonal tumor defined as PNET/cerebral neuroblastoma. Post‐chemotherapy, the resected tumor tissue was no longer WHO Grade IV, but a WHO Grade I ganglioglioma, inferring maturation and differentiation from the original tumor tissue biopsied pre‐treatment 15 . As with all of the cases discussed thus far, there was impressive regression of tumor bulk.…”

Section: Discussionmentioning

confidence: 99%

“…14 The authors also reported six other cases in the literature of patients with medulloblastoma who had post-treatment maturation of tumor specimens into neuronal/glial, neuronal, gangliocytoma, ganglioneurocytoma, and ganglioglioma phenotypes across studies. 14 Additionally, Bidgoli et al 15 reported on a 7-week-old female diagnosed with an embryonal tumor defined as PNET/cerebral neuroblastoma. Post-chemotherapy, the resected tumor tissue was no longer WHO Grade IV, but a WHO Grade I ganglioglioma, inferring maturation and differentiation from the original tumor tissue biopsied pre-treatment.…”

Section: Maintenance and Patient Follow-upmentioning

confidence: 99%

See 4 more Smart Citations

Embryonal tumor with multilayered rosettes: Post‐treatment maturation and implications for future therapy

et al. 2023

View full text Add to dashboard Cite

Background Embryonal tumor with multilayered rosettes (ETMR) is a deadly grade IV pediatric brain tumor. Despite an intensive multimodal treatment approach that includes surgical resection, high‐dose chemotherapy, and radiotherapy, the progression‐free survival at 5 years is less than 30%. Case We report a case of long‐term survival in a 5‐month old female with a large mass in the posterior fossa, diagnosed as ETMR, which subsequently underwent treatment‐induced maturation. Prior to chemotherapy, histopathology revealed an abundance of highly proliferative, undifferentiated cells and multilayered rosette structures. Conversely, post‐treatment histopathology revealed cell populations that differentiated into neuronal and ganglionic phenotypes. At 5‐year follow‐up, the patient remains progression‐free. Conclusion This finding contributes to the few reports to date of post‐treatment differentiation/maturation of ETMR cell populations, with an implication for less cytotoxic therapeutic interventions aimed at differentiation.

show abstract

Section: Discussionmentioning

confidence: 51%

Section: Discussionmentioning

confidence: 97%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Maintenance and Patient Follow-upmentioning

confidence: 99%

See 3 more Smart Citations

Embryonal tumor with multilayered rosettes: Post‐treatment maturation and implications for future therapy

et al. 2023

View full text Add to dashboard Cite

show abstract

Expression Pattern of Tumor-associated Antigens in Neuroblastoma: Association With Cytogenetic Features and Survival

MELESHKO,

KUSHNIAROVA,

SHINKEVICH

et al. 2023

CDP

View full text Add to dashboard Cite

Background/Aim: The prognosis of high-risk and relapsed neuroblastoma (NB) patients remains poor. The identification of tumor-associated markers is important for differential diagnosis, prognosis, and the development of targeted therapies. The aim of the study was to determine the expression profile of nine most common NB antigens and assess their association with clinicopathological characteristics and patient survival. Patients and Methods: Tumor samples from 86 patients with NB were evaluated for the expression of tumor-associated antigen (TAA) using quantitative PCR. Twenty-one patients with benign tumors and 17 healthy donors were assigned as controls. Results: Overexpression of tyrosine hydroxylase (TH), PHOX2B, PRAME, GPC2, B7-H3, and Survivin is the most typical for NB. Positive expression of MAGEA3, MAGEA1, and NY-ESO-1 at low levels was detected in 54%, 48%, and 52%, respectively, and was not NB specific. Higher TH expression was observed in samples without MYCN-amplification, while higher expression of Survivin, PHOX2B, and GPC2 was significantly associated with the presence of 1p.36 deletion. Overexpression of TH, PHOX2B, and MAGEA1 was associated with better event-free (EFS) and overall survival (OS). Survivin overexpression was associated with poor EFS but had no impact on OS. Multivariate analysis confirmed Survivin as independent marker for poor survival, and PHOX2B and MAGEA1 for better survival. Conclusion: High expression of TH, PHOX2B, and MAGEA1 genes are favorable prognostic factors for OS and EFS, whereas high expression of Survivin is associated with an increased risk of relapse or progression.

show abstract

Histologic maturation of cerebral neuroblastoma following conventional chemotherapy

Cited by 2 publications

References 13 publications

Embryonal tumor with multilayered rosettes: Post‐treatment maturation and implications for future therapy

Embryonal tumor with multilayered rosettes: Post‐treatment maturation and implications for future therapy

Expression Pattern of Tumor-associated Antigens in Neuroblastoma: Association With Cytogenetic Features and Survival

Contact Info

Product

Resources

About